Aarti Drugs Ltd
Established in the year 1984 and a part of $1000 million Aarti Group of Industries, Aarti Drugs Ltd. (ADL) is engaged into manufacturing and selling Active Pharmaceutical Ingredients (API's), Pharma Intermediates, Specialty Chemicals as well as Formulations. [1]
It is exporting its API's and Speciality chemicals to over 100 countries across the globe. [2]
- Market Cap ₹ 4,348 Cr.
- Current Price ₹ 470
- High / Low ₹ 512 / 311
- Stock P/E 28.5
- Book Value ₹ 120
- Dividend Yield 0.21 %
- ROCE 15.1 %
- ROE 14.6 %
- Face Value ₹ 10.0
Pros
Cons
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
659 | 826 | 972 | 1,087 | 1,076 | 1,089 | 1,140 | 1,454 | 1,635 | 1,915 | 2,251 | 2,498 | |
579 | 703 | 822 | 915 | 900 | 910 | 955 | 1,252 | 1,387 | 1,511 | 1,930 | 2,216 | |
Operating Profit | 80 | 123 | 150 | 172 | 176 | 179 | 185 | 203 | 248 | 404 | 321 | 282 |
OPM % | 12% | 15% | 15% | 16% | 16% | 16% | 16% | 14% | 15% | 21% | 14% | 11% |
2 | -0 | 1 | 1 | 0 | 4 | 1 | 6 | 9 | 7 | 5 | 2 | |
Interest | 25 | 31 | 37 | 42 | 47 | 38 | 36 | 41 | 36 | 26 | 23 | 33 |
Depreciation | 24 | 26 | 28 | 31 | 36 | 37 | 38 | 40 | 47 | 48 | 47 | 47 |
Profit before tax | 32 | 66 | 86 | 100 | 93 | 108 | 112 | 128 | 175 | 338 | 256 | 205 |
Tax % | 30% | 31% | 28% | 22% | 29% | 30% | 35% | 32% | 22% | 24% | 24% | 25% |
Net Profit | 22 | 45 | 62 | 78 | 66 | 75 | 73 | 87 | 136 | 258 | 195 | 153 |
EPS in Rs | 2.32 | 4.67 | 6.38 | 8.01 | 6.84 | 7.91 | 7.78 | 9.25 | 14.56 | 27.65 | 21.06 | 16.50 |
Dividend Payout % | 27% | 27% | 26% | 41% | 25% | 3% | 3% | 3% | 3% | 9% | 5% | 6% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 17% |
3 Years: | 15% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 13% |
5 Years: | 16% |
3 Years: | 6% |
TTM: | -22% |
Stock Price CAGR | |
---|---|
10 Years: | 33% |
5 Years: | 30% |
3 Years: | 25% |
1 Year: | 10% |
Return on Equity | |
---|---|
10 Years: | 22% |
5 Years: | 22% |
3 Years: | 22% |
Last Year: | 15% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 12 | 12 | 24 | 24 | 24 | 24 | 24 | 23 | 93 | 93 | 93 | |
Reserves | 164 | 196 | 239 | 279 | 326 | 363 | 410 | 495 | 598 | 766 | 880 | 1,022 |
272 | 296 | 342 | 435 | 465 | 448 | 517 | 471 | 378 | 336 | 519 | 535 | |
164 | 216 | 257 | 228 | 240 | 281 | 366 | 384 | 471 | 442 | 543 | 546 | |
Total Liabilities | 613 | 720 | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 |
274 | 291 | 373 | 431 | 463 | 542 | 564 | 586 | 612 | 631 | 649 | 634 | |
CWIP | 3 | 13 | 8 | 13 | 34 | 14 | 28 | 32 | 11 | 16 | 60 | 161 |
Investments | 7 | 5 | 5 | 11 | 11 | 18 | 17 | 19 | 20 | 24 | 28 | 29 |
329 | 411 | 464 | 511 | 547 | 541 | 707 | 736 | 828 | 966 | 1,297 | 1,372 | |
Total Assets | 613 | 720 | 850 | 967 | 1,055 | 1,116 | 1,316 | 1,373 | 1,471 | 1,637 | 2,035 | 2,196 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
44 | 72 | 95 | 107 | 125 | 174 | 62 | 147 | 196 | 154 | 40 | 162 | |
-48 | -58 | -105 | -102 | -87 | -96 | -71 | -59 | -29 | -69 | -125 | -131 | |
3 | -16 | 11 | -5 | -37 | -78 | 9 | -87 | -168 | -85 | 84 | -31 | |
Net Cash Flow | -0 | -2 | 2 | -1 | 1 | -0 | -0 | 1 | -1 | -0 | -1 | 1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 100 | 95 | 104 | 103 | 109 | 93 | 117 | 110 | 104 | 96 | 115 | 117 |
Inventory Days | 80 | 95 | 71 | 77 | 87 | 101 | 132 | 86 | 107 | 125 | 120 | 100 |
Days Payable | 77 | 88 | 84 | 75 | 85 | 91 | 125 | 86 | 110 | 94 | 103 | 88 |
Cash Conversion Cycle | 103 | 101 | 91 | 105 | 110 | 103 | 124 | 109 | 101 | 127 | 133 | 129 |
Working Capital Days | 105 | 101 | 90 | 97 | 108 | 103 | 128 | 108 | 95 | 118 | 132 | 130 |
ROCE % | 14% | 20% | 22% | 21% | 18% | 17% | 17% | 17% | 20% | 33% | 21% | 15% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1d
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 5 Jun
- Reply To Clarification Sought With Respect To Increase In The Volume Of Security Across The Exchange 2 Jun
-
Clarification sought from Aarti Drugs Ltd
2 Jun - Exchange has sought clarification from Aarti Drugs Ltd on June 2, 2023, with reference to Movement in Volume.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 1 Jun
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
Jun 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
May 2019TranscriptNotesPPT
Largest producer in World
Aarti Drugs Ltd. (ADL) is the largest producer of Fluoroquinolones group, Tinidazole, Metronidazole Benzoate, Celecoxib, Nimesulide, and Ketoconazole in the world. It is one of the leading producers of Metformin in the world. [1]